Insights

Strategic Partnership with Eli Lilly Beam Therapeutics' partnership with Eli Lilly presents a sales opportunity for collaboration and potential future joint projects in the field of cardiovascular disease treatments.

Expanding Pharmaceutical Portfolio The development of BEAM-101 for the sickle cell disease (SCD) indication by Beam Therapeutics brings forth a potential sales avenue for partnerships with healthcare institutions and pharmaceutical companies looking to address SCD.

Attraction of Top Talent like Christi Shaw The appointment of biotech executive Christi Shaw to Beam Therapeutics' board of directors enhances the company's credibility and opens doors for potential sales opportunities through networking and industry connections.

Acquisition by Eli Lilly Eli Lilly's acquisition of Beam Therapeutics showcases industry recognition of the company's potential, providing a platform for sales growth and collaboration within Eli Lilly's expansive network.

Emerging Precision Genetic Medicines Beam Therapeutics' pioneering base editing technology offers a unique selling point for engaging with pharmaceutical companies and research institutions seeking innovative precision genetic medicines for various serious diseases.

Similar companies to Beam Therapeutics

Beam Therapeutics Tech Stack

Beam Therapeutics uses 8 technology products and services including MATLAB, NetSuite, Microsoft Excel, and more. Explore Beam Therapeutics's tech stack below.

MATLAB
Advanced Analytics And Data Science
NetSuite
E-commerce
Microsoft Excel
Editors
Oracle
Enterprise
SAP ERP
Enterprise Resource Planning
Google Font API
Font Scripts
ADP HRMS
Human Resource Management System
Minitab
Visualisation Software

Media & News

Beam Therapeutics's Email Address Formats

Beam Therapeutics uses at least 1 format(s):

Beam Therapeutics Email Formats	Example	Percentage
FLast@beamtx.com	JDoe@beamtx.com	97%
FL@beamtx.com	JD@beamtx.com	2%
Last@beamtx.com	Doe@beamtx.com	1%

Frequently Asked Questions

Where is Beam Therapeutics's headquarters located?

Beam Therapeutics's main headquarters is located at 238 Main St Cambridge, Massachusetts 02142 US. The company has employees across 3 continents, including North AmericaEuropeAsia.

What is Beam Therapeutics's phone number?

You can contact Beam Therapeutics's main corporate office by phone at

+1-857-302-****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Beam Therapeutics's stock symbol?

Beam Therapeutics is a publicly traded company; the company's stock symbol is BEAM.

What is Beam Therapeutics's official website and social media links?

Beam Therapeutics's official website is beamtx.com and has social profiles on LinkedIn.

How much revenue does Beam Therapeutics generate?

As of September 2024, Beam Therapeutics's annual revenue reached $750M.

What is Beam Therapeutics's SIC code NAICS code?

Beam Therapeutics's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Beam Therapeutics have currently?

As of September 2024, Beam Therapeutics has approximately 504 employees across 3 continents, including North AmericaEuropeAsia. Key team members include Chief Manufacturing Officer: B. R.Chief Commercial Officer (cco): J. L.Chief Scientific Officer: G. S.. Explore Beam Therapeutics's employee directory with LeadIQ.

What industry does Beam Therapeutics belong to?

Beam Therapeutics operates in the Biotechnology Research industry.

What technology does Beam Therapeutics use?

Beam Therapeutics's tech stack includes MATLABNetSuiteMicrosoft ExcelOracleSAP ERPGoogle Font APIADP HRMSMinitab.

What is Beam Therapeutics's email format?

Beam Therapeutics's email format typically follows the pattern of . Find more Beam Therapeutics email formats with LeadIQ.

How much funding has Beam Therapeutics raised to date?

As of September 2024, Beam Therapeutics has raised $260M in funding. The last funding round occurred on Jan 19, 2021 for $260M.

When was Beam Therapeutics founded?

Beam Therapeutics was founded in 2017.

Beam Therapeutics

Biotechnology ResearchMassachusetts, United States501-1000 Employees

Beam Therapeutics, launched in 2018, is pioneering the use of CRISPR base editing to develop a broad portfolio of advanced genetic medicines. Our groundbreaking base editing technology allows us to make permanent, specific edits to single bases in DNA and RNA, without cutting the strands. Base editor therapeutics represent a new class of “precision genetic medicines,” combining precision targeting of the genome with precision control of editing outcomes. 

Our dream is to provide life-long cures for patients suffering from serious diseases.

The Beam Team Is:
•	A community of fearless innovators
•	Rigorous and honest in our research
•	Listening with open minds
•	Committed to each other

Company Overview

Headquarters: 238 Main St Cambridge, Massachusetts 02142 US
Phone number: ✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
+1-857-302-****
Website: beamtx.com
SIC Code: 8733 - Noncommercial Research Organizations
Stock Symbol: BEAM
NAICS Code: 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded: 2017
Employees: 501-1000

Media & News

Funding & Financials

$260M
Beam Therapeutics has raised a total of $260M of funding over 4 rounds. Their latest funding round was raised on Jan 19, 2021 in the amount of $260M.
$100M$1B
Beam Therapeutics's revenue is in the range of $100M$1B

Funding & Financials

$260M
Beam Therapeutics has raised a total of $260M of funding over 4 rounds. Their latest funding round was raised on Jan 19, 2021 in the amount of $260M.
$100M$1B
Beam Therapeutics's revenue is in the range of $100M$1B

Company Leadership

B. R.
Chief Manufacturing Officer
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. L.
Chief Commercial Officer (cco)
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
G. S.
Chief Scientific Officer
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
C. B.
Chief Legal Officer
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
A. S.
Chief Medical Officer
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Employee Directory

A. S.
Chief Medical Officer
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
F. G.
Chief Scientific Officer
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
M. S.
Chief Technology Officer
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
J. D.
Vice President, Talent Acquisition
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email
V. K.
Vice President Supply Chain
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Mobile Phone
✕
Access Insights for Beam Therapeutics and Millions of Other Companies
Sign up for full access to Beam Therapeutics information.
No credit card needed
OR
Work email
By creating an account, you agree to LeadIQ's Terms of Use and Privacy Policy.
Email

Go to Employee Directory

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

Insights

Similar companies to Beam Therapeutics

Foundation Medicine

Myriad Genetics

Fulgent Genetics

Genomic Health

CRISPR Therapeutics

Sarepta Therapeutics

Editas Medicine

Guardant Health

Natera

PathAI

Beam Therapeutics Tech Stack

Media & News

Terry-Ann Burrell left Beam Therapeutics Inc. as chief financial officer on Jul 15th '24.

Beam Therapeutics Inc. is developing BEAM-101 for the SCD indication in early-stage studies.

Beam Therapeutics Inc. hired Christi Shaw as board of directors on Dec 14th '23.

Eli Lilly acquires Beam Therapeutics Inc. for $600M.

Beam Therapeutics Inc. partnered with Eli Lilly on Nov 7th '23.

Beam Therapeutics Inc. sells assets to Eli Lilly in the amount of $250M.

Verve Therapeutics, Inc. partnered with Beam Therapeutics Inc. on Apr 1st '19.

Beam Therapeutics's Email Address Formats

Frequently Asked Questions

Where is Beam Therapeutics's headquarters located?

What is Beam Therapeutics's phone number?

What is Beam Therapeutics's stock symbol?

What is Beam Therapeutics's official website and social media links?

How much revenue does Beam Therapeutics generate?

What is Beam Therapeutics's SIC code NAICS code?

How many employees does Beam Therapeutics have currently?

What industry does Beam Therapeutics belong to?

What technology does Beam Therapeutics use?

What is Beam Therapeutics's email format?

How much funding has Beam Therapeutics raised to date?

When was Beam Therapeutics founded?

Beam Therapeutics

Company Overview

Media & News

Terry-Ann Burrell left Beam Therapeutics Inc. as chief financial officer on Jul 15th '24.

Beam Therapeutics Inc. is developing BEAM-101 for the SCD indication in early-stage studies.

Beam Therapeutics Inc. hired Christi Shaw as board of directors on Dec 14th '23.

Funding & Financials

Funding & Financials

Company Leadership

Employee Directory

Ready to create more pipeline?

Ready to create more pipeline?